Translational longevity medicine: a Swiss perspective in an ageing country.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
30 06 2023
Historique:
medline: 10 7 2023
pubmed: 6 7 2023
entrez: 6 7 2023
Statut: epublish

Résumé

Breakthroughs in medical research in the last century have led to a significant extension of the human lifespan, resulting in a shift towards an elderly population worldwide. Due to the ongoing progress of global development towards elevated standards of living, this study specifically examines Switzerland as a representative nation to explore the socioeconomic and healthcare ramifications associated with an ageing population, thereby highlighting the tangible impact experienced in this context. Beyond the exhaustion of pension funds and medical budgets, by reviewing the literature and analysing publicly available data, we observe a "Swiss Japanification". Old age is associated with late-life comorbidities and an increasing proportion of time spent in poor health. To address these problems, a paradigm shift in medical practice is needed to improve health rather than respond to existing diseases. Basic ageing research is gaining momentum to be translated into therapeutic interventions and provides machine learning tools driving longevity medicine. We propose that research focus on closing the translational gap between the molecular mechanisms of ageing and a more prevention-based medicine, which would help people age better and prevent late-life chronic diseases.

Identifiants

pubmed: 37410895
pii: 40088
doi: 10.57187/smw.2023.40088
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

40088

Auteurs

Marco M Ruckstuhl (MM)

Laboratory of Extracellular Matrix Regeneration, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zürich, Schwerzenbach, Switzerland.

Evelyne Bischof (E)

Shanghai University of Medicine and Health Sciences, Shanghai, China.
Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Dana Blatch (D)

International Center for Multimorbidity and Complexity in Medicine (ICMC), University of Zurich.

Aliki Buhayer (A)

International Center for Multimorbidity and Complexity in Medicine (ICMC), University of Zurich.
Prism Scientific Sàrl, Genève, Switzerland.

Jörg Goldhahn (J)

Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zürich, Switzerland.

Edouard Battegay (E)

International Center for Multimorbidity and Complexity in Medicine (ICMC), University of Zurich.
Department of Psychosomatic Medicine, Merian Iselin Klinik, Basel, Switzerland.

Andre Tichelli (A)

Division of Haematology, University Hospital Basel, Basel, Switzerland.

Collin Y Ewald (CY)

Laboratory of Extracellular Matrix Regeneration, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zürich, Schwerzenbach, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH